Bottom Line:

Publication details:

Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse (patient version).

We assessed this page using an appraisal instrument developed by Minervation specifically for this project. This approach is still in development, so you should regard the assessments as a general guide. Click here to find out more, or to let us know how you think the approach could be improved.

Reliability comments:

• The site does not report a quality control or content production policy.
• However, most of the pages are clearly prepared with care and based on literature searching and appraisal.

Usability comments:

• The website does not conform to web accessibility standards

Scoring

Date rated

Sep 08

Source

National Cancer Institute (NCI)

Currency

Good

Audience

Patients

Publication Type

Primary research

Format

Reliability

Usability